このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Ind-Swift マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Gopal Munjal

最高経営責任者

₹18.0m

報酬総額

CEO給与比率	100.0%
CEO在任期間	16.3yrs
CEOの所有権	3.6%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	16yrs

経営陣の近況

Recent updates

CEO報酬分析

Ind-Swift の収益と比較して、Gopal Munjal の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	₹142m
Dec 31 2023	n/a	n/a	₹298m
Sep 30 2023	n/a	n/a	₹437m
Jun 30 2023	n/a	n/a	₹438m
Mar 31 2023	₹18m	₹18m	₹260m
Dec 31 2022	n/a	n/a	-₹318m
Sep 30 2022	n/a	n/a	-₹375m
Jun 30 2022	n/a	n/a	-₹319m
Mar 31 2022	₹18m	₹18m	-₹200m
Dec 31 2021	n/a	n/a	-₹320m
Sep 30 2021	n/a	n/a	-₹272m
Jun 30 2021	n/a	n/a	-₹245m
Mar 31 2021	₹15m	₹15m	-₹298m
Dec 31 2020	n/a	n/a	-₹171m
Sep 30 2020	n/a	n/a	-₹277m
Jun 30 2020	n/a	n/a	-₹254m
Mar 31 2020	₹12m	₹12m	-₹191m
Dec 31 2019	n/a	n/a	-₹4m
Jun 30 2019	n/a	n/a	₹48m
Mar 31 2019	₹12m	₹12m	₹82m
Mar 31 2018	₹12m	₹12m	-₹504m

報酬と市場: Gopalの総報酬 ($USD 215.75K ) は、 Indian市場 ($USD 38.34K ) の同規模の企業の平均を上回っています。

報酬と収益: Gopalの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Gopal Munjal (66 yo)

16.3yrs

在職期間

₹18,000,000

報酬

Dr. Gopal Munjal, M.D. has been the Chief Executive Officer and Managing Director of Ind-Swift Ltd. since April 2008. Dr. Munjal has experience in Pharmaceutical industry.Dr. Munjal served as the Chairman...

取締役

名称	ポジション	在職期間	報酬	所有権
Sanjeev Mehta	Executive Chairman	17.7yrs	₹18.00m	3.76% ₹ 43.9m
Gopal Munjal	CEO, MD & Whole Time Director	37.6yrs	₹18.00m	3.61% ₹ 42.2m
Vikrant Mehta	Joint MD & Whole Time Director	30.8yrs	₹18.00m	3.55% ₹ 41.4m
Navrattan Munjal	Non-Executive Director	37.6yrs	₹65.00k	1.37% ₹ 15.9m
Himanshu Jain	Non-Executive Director	20.9yrs	₹85.00k	0.91% ₹ 10.7m
Rishav Mehta	Non-Executive Director	14.3yrs	₹45.00k	0.21% ₹ 2.4m
Subhash Galhotra	Independent Director	7.6yrs	₹70.00k	データなし
Anoop Michra	Independent Woman Director	7.2yrs	₹55.00k	データなし
Jagvir Ahluwalia	Non-Executive Independent Director	6.9yrs	₹70.00k	データなし
Bhupinder Singh	Non-Executive Independent Director	2.1yrs	₹55.00k	データなし

16.0yrs

平均在職期間

66yo

平均年齢

経験豊富なボード: 524652の取締役会は経験豊富で経験豊富です ( 15.9年の平均在任期間)。

Ind-Swift マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent Director

Ind-Swift Limited, Annual General Meeting, Sep 30, 2023

Insufficient new directors

Ind-Swift Approves Appointment of Sh. Bhupinder Singh as an Independent Director

Ind-Swift Limited, Annual General Meeting, Sep 21, 2022

Ind-Swift Limited Appoints Ginny Uppal as Company Secretary and Compliance Officer

Recent updates

New minor risk - Earnings quality

Full year 2024 earnings released: EPS: ₹2.63 (vs ₹4.81 in FY 2023)

Ind-Swift Limited to Report Q4, 2024 Results on May 14, 2024

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 29%

Investor sentiment improves as stock rises 21%

Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent Director

Investor sentiment improves as stock rises 16%

Third quarter 2024 earnings released: ₹2.76 loss per share (vs ₹0.19 loss in 3Q 2023)

Investor sentiment improves as stock rises 18%

Ind-Swift Limited to Report Q3, 2024 Results on Feb 13, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: ₹1.98 loss per share (vs ₹1.96 loss in 2Q 2023)

Ind-Swift Limited to Report Q2, 2024 Results on Nov 09, 2023

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 21%

First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹2.85 loss in 1Q 2023)

Ind-Swift Limited to Report Q1, 2024 Results on Aug 10, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: ₹4.81 (vs ₹3.70 loss in FY 2022)

Ind-Swift Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released

Ind-Swift Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: ₹1.96 loss per share (vs ₹0.91 loss in 2Q 2022)

Insufficient new directors

Ind-Swift Limited to Report Q2, 2023 Results on Nov 14, 2022

Ind-Swift Approves Appointment of Sh. Bhupinder Singh as an Independent Director

First quarter 2023 earnings released: ₹2.85 loss per share (vs ₹0.66 loss in 1Q 2022)

Ind-Swift Limited, Annual General Meeting, Sep 21, 2022

Ind-Swift Limited to Report Q1, 2023 Results on Aug 09, 2022

Full year 2022 earnings released: ₹3.70 loss per share (vs ₹5.51 loss in FY 2021)

Ind-Swift Limited Appoints Ginny Uppal as Company Secretary and Compliance Officer

Ind-Swift Limited to Report Q4, 2022 Results on May 30, 2022

Less than half of directors are independent

Ind-Swift Limited Announces the Resignation of Amrender Kumar Yadav as Company Secretary & Compliance Officer

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ind-Swift Limited to Report Q3, 2022 Results on Feb 14, 2022

First quarter 2022 earnings released: ₹0.66 loss per share (vs ₹1.64 loss in 1Q 2021)

ANG Lifesciences India Limited (BSE:540694) acquired Two Formulation Manufacturing Facilities from Ind-Swift Limited (BSE:524652) for INR 600 million.

Full year 2021 earnings released: ₹5.50 loss per share (vs ₹3.53 loss in FY 2020)

Third quarter 2021 earnings released: ₹0.22 loss per share (vs ₹2.18 loss in 3Q 2020)

Ind-Swift Limited to Report Q3, 2021 Results on Feb 13, 2021

New 90-day low: ₹3.01

Second quarter 2021 earnings released: ₹0.42 loss per share

New 90-day high: ₹3.59

New 90-day high - ₹3.50

Earnings released

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24